Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q4 2017 call → NOThe question asks whether management repeatedly redirects attention away from the conventional yardstick toward a different part of the business that is already earning today, and indicates that the record has not caught up. Let me analyze the transcript. The company is Pacira Pharmaceuticals, selling EXPAREL, a non-opioid pain management drug. The conventional yardstick would be EXPAREL sales, growth rates, guidance, etc. Looking at the call, management discusses: - EXPAREL sales guidance for 2018 - J&J partnership - Clinical trials - CMS reimbursement - Various partnerships The question is whether management redirects attention away from the conventional measure (EXPAREL sales growth) toward a different part of the business that is already earning. Let me look for evidence of this pattern. Management discusses many things: clinical programs, partnerships, CMS reimbursement, J&J collaboration. But does it set aside the conventional yardstick (EXPAREL sales) and point to something else already earning? The call is largely organized around EXPAREL sales, guidance, J&J partnership, clinical development, reimbursement. The conventional yardstick is EXPAREL revenue growth. Management gives guidance of $300-310 million for 2018. Is there a different part of the business that management says is already earning but not reflected in results? The partnerships (Trinity, Aetna, etc.) are discussed as drivers but not as separate earning businesses. The CMS reimbursement is prospective. The J&J partnership is a co-promotion that drives EXPAREL sales. Management does discuss the guidance being conservative, and mentions that various initiatives (CMS, nerve block, etc.) make timing difficult. But this is about the core product's growth trajectory, not about redirecting to a different part of the business. The call seems to be a conventional earnings call organized around EXPAREL sales, guidance, pipeline, and partnerships. Management isn't setting aside the conventional yardstick and pointing to a different earning engine. The partnerships and initiatives are all in service of EXPAREL sales growth. There's no clear pattern of management saying "the metric you watch is no longer the right one" and pointing to something else already earning. The discussion is about the core product's growth drivers. Answer: NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.